tiprankstipranks
Intellia Therapeutics (NTLA)
NASDAQ:NTLA
Holding NTLA?
Track your performance easily

Intellia Therapeutics (NTLA) Ownership - Who Owns Intellia Therapeutics?

3,122 Followers

Intellia Therapeutics (NTLA) Ownership Overview

1.74%21.73%35.37%30.70%10.46%
35.37% Other Institutional Investors
30.70% ETFs
10.46% Public Companies and Individual Investors
The ownership structure of Intellia Therapeutics (NTLA) stock is a mix of institutional, retail, and individual investors. Approximately 87.80% of the company’s stock is owned by Institutional Investors, 1.74% is owned by Insiders, and 10.46% is owned by Public Companies and Individual Investors.
The ownership structure of {name} ({ticker}) stock is a mix of institutional, retail, and individual investors. {displayInstitutionalData, select, display {Approximately {institutionalPercentage} of the company’s stock is owned by Institutional Investors} other {}}{displayInsiderText, select, display {, {insidersPercentage} is owned by Insiders} other {}}{displayInvestorsText, select, display {, and {retailInvestorsPercentage} is owned by Public Companies and Individual Investors.} other {}}

Recent Insider Trading Activity

Date
Name
Activity
Value
Oct 04, 2024
xxxxxxxxxxxxx
$38248
Mar 05, 2024
Eliana Clark
Evp, Cto
xxxxxxxxxxxxx
$19959
Mar 05, 2024
James Basta
Evp & Gc
xxxxxxxxxxxxx
$75778
Jan 05, 2024
Eliana Clark
Evp, Cto
xxxxxxxxxxxxx
$126707

Recent Hedge Fund Trading Activity

Date
Firm
Activity
Value
Sep 30, 2024
xxxxxxxxxxxxx
$251849292

Top Shareholders

Holder
# of Shares
Type
% Holding
Value
12,255,440Institution12.03%173,169,367
11,686,487Institution11.47%165,130,061
9,337,270Institution9.17%131,935,625
7,944,720Institution7.80%112,258,894
4,648,085Institution4.56%65,677,441
3,125,463Institution3.07%44,162,792
2,260,875Institution2.22%31,946,164
1,658,211Institution1.63%23,430,521
1,104,841Institution1.08%15,611,403
1,046,065Institution1.03%14,780,898

Top Mutual Fund Holders

Holder
# of Shares
Type
% Holding
Value
7,944,720Institution7.80%112,258,894
2,260,875Institution2.22%31,946,164
1,658,211Institution1.63%23,430,521
1,104,841Institution1.08%15,611,403
1,046,065Institution1.03%14,780,898
981,815Institution0.96%13,873,046
818,179Institution0.80%11,560,869
513,980Institution0.50%7,262,537
499,045Institution0.49%7,051,506
463,073Institution0.45%6,543,221

Top ETF Holders

Holder
# of Shares
Type
% Holding
Value
8,405,956Institution8.25%118,776,158
3,171,588Institution3.11%65,176,133
2,411,725Institution2.37%49,560,949
3,034,708Institution2.98%42,880,424
2,701,156Institution2.65%38,275,381
2,650,977Institution2.60%37,458,305
1,521,149Institution1.49%31,259,612
1,332,207Institution1.31%27,376,854
924,890Institution0.91%13,068,696
703,757Institution0.69%9,944,086

FAQ

Who Owns Intellia Therapeutics (NTLA)?
According to the latest TipRanks data, approximately 35.37% of the company's stock is held by institutional investors, 1.74% is held by insiders, and 10.46% is held by retail investors.
    What percentage of Intellia Therapeutics (NTLA) stock is held by institutional investors?
    According to the latest TipRanks data, approximately 35.37% of Intellia Therapeutics (NTLA) stock is held by institutional investors.
      What percentage of Intellia Therapeutics (NTLA) stock is held by retail investors?
      According to the latest TipRanks data, approximately 10.46% of Intellia Therapeutics (NTLA) stock is held by retail investors.
        Who owns the most shares of Intellia Therapeutics (NTLA)?
        Cathie Wood owns the most shares of Intellia Therapeutics (NTLA).
          What is the significance of the ownership structure for a publicly traded company?
          The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis